Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: apoptosis inducers - EpiCept Corporation

Next Previous
X
Search
Drug Profile

Research programme: apoptosis inducers - EpiCept Corporation

Alternative Names: CV 2116; CV 43468; CV 55510; CV 58211; EP128504; EP129168; EP2161; EP95615; EPC 2167; Gambogic acid; MX 128504; MX 2060; MX 2167; MX 59003; MX 63844; MX 69501; MX 72086; MX 73883; MX 73936; MX 74420; MX 76629; MX 77356

Latest Information Update: 16 Jul 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EpiCept Corporation
  • Developer Immune Pharmaceuticals Inc
  • Class Fluorenes; Nicotinic acids; Pyrimidines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Caspase stimulants; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
  • 20 Aug 2013 EpiCept Corporation has been acquired by Immune Pharmaceuticals Ltd
  • 26 Mar 2009 In vitro data presented at the 237th American Chemical Society National Meeting (ACS-2009)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top